Beijing's stand on Masood doing material harm to China-India ties: Experts

Agencies
November 7, 2017

Washington, Nov 7: The recent decision by China to block a bid at the United Nations to list Maulana Masood Azhar, chief of Pakistan-based Jaish-e-Mohammed (JeM) militant group, as a global terrorist, is doing "material harm" to its ties with India, top American experts said today.

Last week, China had blocked a bid at the United Nations by the US, France, and Britain to list Azhar as a global terrorist, citing a lack of consensus among the members of the UN Security Council.

A veto-wielding permanent member of the UN Security Council, China has repeatedly blocked Indias move to designate Azhar a terrorist under the Al-Qaeda Sanctions Committee of the UN Security Council.

"I think it's an unfortunate move on China's part and I question the logic of continuing to block sanctions on known Pakistan-based terrorists at the United Nations," Jeff Smith from the Heritage Foundation said.

Smith said that China was "clearly" seeing its action as a favor to its all-weather friend, Pakistan.

"But the policy is increasingly undermining China's own strategic interests and stated foreign policy objectives," he said, noting that in September, China had, for the first time, relented to including specific criticism of JeM and other Pakistani terror outfits in the statement issued at the BRICS summit in Xiamen.

"It grievously undermines an increasingly prominent Chinese narrative about the need to take a tougher line on terrorism broadly, and in Afghanistan specifically," Smith said.

"It's actions are also doing material harm to the health of a China-India relationship already under duress," he said.

The Permanent Mission of the United States to the United Nations said that the Committee discussions over whether to add an individual or entity to the 1267 sanctions list are confidential to the committee.

"However, we would support efforts to list Azhar, Jaish-e Mohammeds founder and leader, on the 1267 Sanctions List and would encourage others to support his listing as well," a spokesperson for the US mission in New York said.

According to Rick Rossow from Center for Strategic and International Studies (CSIS), an American think-tank, China's latest move affirmed Delhi's belief in Sino-Pakistani collusion.

"By supporting this decision, China could have taken an important step to restart its ties with Delhi, yet Beijing chose a different path," Rossow said.

Rossow alleged that China continued to use the international system where it saw fit, "such as this vote", while undermining the international system in other areas, "such as maritime law".

"The timing is significant, coming on the heels of Washingtons stronger rhetoric against Pakistans support for terrorism. Much like the announcement of the China-Pakistan Economic Corridor, this decision was another Chinese lifeline to Islamabad at a precarious time," Rossow said.

Director of Initiative on the Future of India and South Asia at Hudson Institute think tank, Aparna Pande, said she was not surprised by Beijing's decision.

"While China worries about Islamist radicals it is concerned primarily with Uyghurs and on that front it will apply pressure on Pakistan," she noted.

"When it comes to Jihadis that target India, China does not see it as in its interest to force Pakistan. Further, being seen as Pakistans benefactor in the international arena is another benefit for Beijing," Pande said. The JeM, founded by Azhar, has already been in the UNs list of banned terror outfits.

Last year in March, China was the only member in the 15- nation UN Security Council to put a hold on Indias application.

The other 14 members supported New Delhis bid to place Azhar on the sanctions list that would subject him to an assets freeze and travel ban.

Azhar is accused of several terrorist attacks in India, including one on the Pathankot air force station in January 2016.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
March 4,2020

Tokyo, Mar 4: Takeda Pharmaceutical Co said on Wednesday it was developing a drug to treat COVID-19, the flu-like illness that has struck more than 90,000 people worldwide and killed over 3,000.

The Japanese drugmaker is working on a plasma-derived therapy to treat high-risk individuals infected with the new coronavirus and will share its plans with members of the U.S. Congress on Wednesday, it said in a statement.

Takeda is also studying whether its currently marketed and pipeline products may be effective treatments for infected patients.

"We will do all that we can to address the novel coronavirus threat...(and) are hopeful that we can expand the treatment options," Rajeev Venkayya, president of Takeda's vaccine business, said in the statement.

Takeda said it was in talks with various health and regulatory agencies and healthcare partners in the United States, Asia and Europe to move forward its research into the drug.

Its research requires access to the blood of people who have recovered from the respiratory disease or who have been vaccinated, once a vaccine is developed, Takeda said.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
January 6,2020

Aboard Air Force One, Jan 6: US President Donald Trump threatened sanctions against Baghdad on Sunday after Iraq's parliament called on US troops to leave the country, and the president said if troops did leave, Baghdad would have to pay Washington for the cost of the air base there.

"We have a very extraordinarily expensive air base that's there. It cost billions of dollars to build, long before my time. We're not leaving unless they pay us back for it," Trump told reporters on Air Force One.

Trump said that if Iraq asked US forces to leave and it was not done on a friendly basis, "we will charge them sanctions like they've never seen before ever. It'll make Iranian sanctions look somewhat tame."

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
May 19,2020

Washington, May 19: As the scientists across the world are struggling to develop a vaccine for combating coronavirus, US drugmaker Moderna announced on Monday (local time) that the phase I trial of its Covid-19 vaccine has shown positive early results.

The company is hopeful that it's vaccine could be available to the public as early as January next year. Several firms across the world are in the race to develop a vaccine for the deadly virus which has claimed over 3 lakh lives worldwide.

CNN citing Dr. Tal Zaks, Moderna's chief medical officer reported that "if future studies go well, the company's vaccine could be available to the public as early as January".

"This is absolutely good news and news that we think many have been waiting for for quite some time," Zaks was quoted as saying.

Moderna, based in Cambridge, Massachusetts announced that the vaccine developed neutralising antibodies to the virus at levels reaching or exceeding the levels seen in people who have naturally recovered from Covid-19, reported CNN.

These will be followed by phase 2 trials and phase 3 trials, which Moderna plans to start in July.

President Donald Trump had on Friday said that that the United States will be able to deliver a few hundred million doses of COVID-19 vaccine, under 'Operation Warp Speed', by the end of this year.

"I have very recently seen early data from a clinical trial with a coronavirus vaccine and this data made me feel even more confident that we'll be able to deliver a few hundred million doses of vaccine by the end of 2020 and we will do the best we can," Trump had said at a press conference at the White House on Friday.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.